Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgements
- Introduction
- Part I Sectoral systems: concepts and issues
- Part II Six sectoral systems
- 3 Pharmaceuticals analyzed through the lens of a sectoral innovation system
- 4 The chemical sectoral system: firms, markets, institutions and the processes of knowledge creation and diffusion
- 5 The fixed Internet and mobile telecommunications sectoral system of innovation: equipment production, access provision and content provision
- 6 The European software sectoral system of innovation
- 7 Machine tools: the remaking of a traditional sectoral innovation system
- 8 Services and systems of innovation
- Part III Sectoral systems and national systems; international performance and public policy
- Part IV Conclusions
- Index
- References
3 - Pharmaceuticals analyzed through the lens of a sectoral innovation system
Published online by Cambridge University Press: 22 September 2009
Edited by
Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgements
- Introduction
- Part I Sectoral systems: concepts and issues
- Part II Six sectoral systems
- 3 Pharmaceuticals analyzed through the lens of a sectoral innovation system
- 4 The chemical sectoral system: firms, markets, institutions and the processes of knowledge creation and diffusion
- 5 The fixed Internet and mobile telecommunications sectoral system of innovation: equipment production, access provision and content provision
- 6 The European software sectoral system of innovation
- 7 Machine tools: the remaking of a traditional sectoral innovation system
- 8 Services and systems of innovation
- Part III Sectoral systems and national systems; international performance and public policy
- Part IV Conclusions
- Index
- References
Summary
Introduction
This chapter analyzes the pharmaceutical industry through the lens of a sectoral system of innovation. Intuitively, the pharmaceutical industry quite naturally lends itself to be analyzed as an SSI or as a network (see Galambos and Sewell, 1995; Chandler, 1990; Gambardella, Orsenigo and Pammolli, 2000; and McKelvey and Orsenigo, 2002). However, at the same time and precisely given the intuitive appeal of the notion of “system” and/or “network” for this industry, taking this approach forces the researcher to try to make this notion more precise and compelling and – above all – to clarify why and in what sense a “sectoral innovation system” approach is useful. This constitutes the general aim of this chapter.
Generically, the pharmaceutical industry can easily be considered as a system or a network because innovative activities involve, directly or indirectly, a large variety of actors, including: (different types of) firms; other research organizations, such as universities and other research centers; financial institutions; regulatory authorities; and consumers.
An innovation system or network is composed of actors, relationships among actors and other contextual features that affect the decisions of actors' behavior and the development of knowledge and economic competencies (Edquist and McKelvey, 2000). All the actors mentioned above are part of an SSI, and they are different in many senses. They know different things; they have different rules of action; they have different incentives and motivations, which may often conflict.
- Type
- Chapter
- Information
- Sectoral Systems of InnovationConcepts, Issues and Analyses of Six Major Sectors in Europe, pp. 73 - 120Publisher: Cambridge University PressPrint publication year: 2004
References
, and (1994), The changing technology of technical change: general and abstract knowledge and the division of innovative labor, Research Policy, 23, 5, 523–532CrossRefGoogle Scholar
Arora A., A. Gambardella, F. Pammolli and M. Riccaboni (2000), Advantage Lost? On the Leveling Effect of the Market for Technology in Biopharmaceuticals, paper prepared for the International Conference on Technology Policy and Innovation, Paris
Arrow, K. J. (1962), Economic welfare and the allocation of resources for investment, in R. R. Nelson (ed.), The Rate and Direction of Inventive Activities: Economic and Social Factors Princeton University Press, Princeton, NJ, 609–625
Arrow, K. J. (1983), Innovation in large and small firms, in J. Ronen (ed.), Entrepreneurship, Lexington Books, Lexington, MA, 15–28
Ben-David, J. (1977), Centers of Learning: Britain, France, Germany and the United States, McGraw-Hill, New York
Braun, D. (1994), Structure and Dynamics of Health Research and Public Funding: An International Institutional Comparison, Kluwer Academic, Amsterdam
Burstall, S. (1985), The Community Pharmaceutical Industry, European Commission, Brussels
Casper, S., and H. E. Kettler (2000), The Road to Sustainability in the UK and German Biotechnology Industries, paper prepared for ESSY conference, Berlin, June 1–3
Chandler, A. D. (1990), Scale and Scope: The Dynamics of Modern Capitalism, Belknap Press of Harvard University Press, Cambridge, MA
Chien, R. I. (1979), Issues in Pharmaceutical Economics, Lexington Books, Lexington, MA
, and (1996), Public-private interaction in pharmaceutical research, Proceedings of the National Academy of Sciences, 93, 23, 12,725–12,730CrossRefGoogle ScholarPubMed
, and (2000), Untangling the origins of competitive advantage, Strategic Management Journal, 21, 10–11, 1,123–1, 1453.0.CO;2-R>CrossRefGoogle Scholar
(1986), The political economy of the pharmaceutical industry, Journal of Economic Literature, 24, 1,178–1,217Google ScholarPubMed
, and (1992), Analyzing the economic payoffs from basic research, Economics of Innovation and New Technology, 2, 73–90CrossRefGoogle Scholar
Edquist, C., and M. McKelvey (eds.) (2000), Systems of Innovation: Growth, Competitiveness and Employment, Reference Collection (two volumes), Edward Elgar Publishing, Cheltenham
(1996), Public research and private development: patents and technology transfer in government-sponsored research, Virginia Law Review, 82, 1,663–1,727CrossRefGoogle Scholar
Galambos, L., and J. E. Sewell (1995), Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895–1995, Cambridge University Press, New York
, and (1998), Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation, Business History Review, 72, 250–278CrossRefGoogle Scholar
Gambardella, A. (1995), Science and Innovation – The US Pharmaceutical Industry during the 1980s, Cambridge University Press, Cambridge
Gambardella, A., L. Orsenigo and F. Pammolli (2000), Global Competitiveness in Pharmaceuticals: A European Perspective, report prepared for the Directorate- General Enterprise of the European Commission
Gittelman, M. (2000), Scientists and Networks: A Comparative Study of Cooperation in the French and American Biotechnology Industry, Ph.D. thesis, Wharton School, University of Pennsylvania
Grabowski, H. G., and J. M. Vernon (1983), The Regulation of Pharmaceuticals, American Enterprise Institute for Public Policy Research, Washington, DC, and London
, and (1994), Innovation and structural change in pharmaceuticals and biotechnology, Industrial and Corporate Change, 3, 2, 435–449CrossRefGoogle Scholar
(1973), The strength of weak ties, American Journal of Sociology, 78, 6, 1,360–1,380CrossRefGoogle Scholar
, and (1996), Scale, scope and spillovers: the determinants of research productivity in drug discovery, RAND Journal of Economics, 27, 1, 32–59CrossRefGoogle ScholarPubMed
Henderson, R., L. Orsenigo and G. P. Pisano (1999), The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organizational change, in D. C. Mowery and R. R. Nelson (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge, 267–311CrossRef
Jacobzone, S. (2000), Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals, Occasional Paper no. 40, Labour Market and Social Policy Series, Organisation for Economic Co-operation and Development, Paris
Kenney, M. (1986), Biotechnology: The Industry-University Complex, Cornell University Press, Ithaca, NY
Kogut, B., W. Shan and G. Walker (1992), The make or cooperate decision in the context of an industry network, in N. Nohria and R. G. Eccles (eds.), Networks and Organizations, Harvard Business School Press, Cambridge, MA, 348–365
Lacetera, N. and L. Orsenigo (2001), Political and Technological Regimes in the Evolution of the Pharmaceutical Industry in the USA and in Europe, paper prepared for the Conference on Evolutionary Economics, Johns Hopkins University, Baltimore, March 30–31
, , and (1987), Appropriating the returns from industrial research and development, Brookings Papers on Economic Activity, 3, 783–831CrossRefGoogle Scholar
McKelvey, M. (1996), Evolutionary Innovation: The Business of Biotechnology, Oxford University Press, Oxford
(1997a), Coevolution in commercial genetic engineering, Industrial and Corporate Change, 6, 3, 503–532CrossRefGoogle Scholar
McKelvey, M. (1997b), Using evolutionary theory to define systems of innovation, in C. Edquist (ed.) (1997), Systems of Innovation: Technologies, Institutions and Organisations, Frances Pinter, London, 200–222
McKelvey, M., and L. Orsenigo (2002), European pharmaceuticals as a sectoral innovation system: performance and national selection environments, submitted for review to Journal of Evolutionary Economics
(1999), Market structure, R&D, and advertising in the pharmaceutical industry, Journal of Industrial Economics, 48, 2, 169–194Google Scholar
Maxwell, R. A., and S. B. Eckhardt (1990), Drug Discovery: A Casebook and Analysis, Humana Press, Clifton, NJ
, and (1998a), The benefits and costs of strong patent protection: a contribution to the current debate, Research Policy, 27, 3, 273–284CrossRefGoogle Scholar
, and (1998b), Economic theories about the benefits and costs of patents, Journal of Economic Issues, 32, 1,031–1,052CrossRefGoogle Scholar
, and (1994), On limiting or encouraging rivalry in technical progress: the effect of patent scope decisions, Journal of Economic Behavior and Organization, 25, 1–24CrossRefGoogle Scholar
Merton, D. (1973), The Sociology of Science: Theoretical and Empirical Investigation, University of Chicago Press, Chicago
(1997), Citizens' view on health systems in the 15 member states of the European Union, Health Economics, 6, 109–1163.0.CO;2-L>CrossRefGoogle Scholar
(1998), The changing structure of the US national innovation system: implications for international conflict and cooperation in R&D policy, Research Policy, 27, 6, 639–654CrossRefGoogle Scholar
Mowery, D. C., and N. Rosenberg (2000), Paths of Innovation: Technological Change in 20th Century America, Cambridge University Press, New York
(1959), The simple economics of basic scientific research, Journal of Political Economy, 67, 297–306CrossRefGoogle Scholar
, and (1994), American universities and technical advance in industry, Research Policy, 23, 3, 323–348Google Scholar
Nelson, R. R., and B. N. Sampat (2000), Making sense of institutions as a factor shaping economic performance, Journal of Economic Behavior and Organization, forthcoming
Orsenigo, L. (1989), The Emergence of Biotechnology, Frances Pinter, London
, and (2001), Technological change and network dynamics, Research Policy, 30, 5, 485–508CrossRefGoogle Scholar
Office of Technology Assessment (1984), Commercial Biotechnology: An International Analysis, US Government Printing Office, Washington, DC
Pammolli, F. (1997), Innovation and Industry Structure: The International Pharmaceutical Industry During the Nineties, Guerini, Milan
Peltzman, S. (1974), Regulation of Pharmaceutical Innovation: The 1962 Amendments, American Enterprise Institute for Public Policy Research, Washington, DC
(1991), The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry, Research Policy, 20, 2, 237–249CrossRefGoogle Scholar
Pisano, G. (1997), R&D Performance, Collaborative Arrangements and the Market for Know-how: A Test of the “Lemons” Hypothesis in Biotechnology, working paper, Harvard Business School
, and (1996), Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology, Administrative Science Quarterly, 41, 116–145CrossRefGoogle Scholar
Schwartzman, D. (1976), Innovation in the Pharmaceutical Industry, Johns Hopkins University Press, Baltimore
Sutton, J. (1998), Technology and Market Structure: Theory and History, MIT Press, Cambridge, MA
(1986), Profiting from technological innovation: implications for integration, collaboration, licensing and public policy, Research Policy, 15, 6, 185–219CrossRefGoogle Scholar
(1994), Implicit industrial policy: the triumph of Britain and the failure of France in global pharmaceuticals, Industrial and Corporate Change, 3, 2, 451–489CrossRefGoogle Scholar
, and (1995), The vertical chain of R&D in the pharmaceutical industry, Economic Inquiry, 33, 1–18CrossRefGoogle Scholar
Zucker, L., M. Darby and M. Brewer (1997), Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises, Working Paper no. 4,653, National Bureau of Economic Research, Boston
- 34
- Cited by